Skip to search formSkip to main contentSkip to account menu

vardenafil

Known as: Vardenafilum, Vardénafil, 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-F][1,2,4]triazin-4(1H)-one 
A benzenesulfonamide derivative and phosphodiesterase type 5 (PDE5) inhibitor with vasodilatory activity. Vardenafil selectively inhibits PDE5, thus… 
National Institutes of Health

Related topics

Related topics

9 relations

Narrower (3)

LevitraVardenafil hydrochlorideVardenafil hydrochloride trihydrate
NitratesNitroglycerinVardenafil:MCnc:Pt:Bld:QnVardenafil:MCnc:Pt:Ser/Plas:Qn

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Modulation of high affinity ATP-dependent cyclic nucleotide transporters by specific and non-specific cyclic nucleotide phosphodiesterase inhibitors.
2011
2011
The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double‐blind laboratory setting study
Study Type – Therapy (RCT)
Level of Evidence 1b 
2011
2011
Identification of novel sildenafil-analogues in an adulterated herbal food supplement.
2010
2010
Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: results of a randomized, double blind, placebo-controlled pilot study.
INTRODUCTION Phosphodiesterase type 5 inhibitors (PDE5-I) have acquired an established role in the treatment of post… 
2007
2007
Functional responses of isolated human seminal vesicle tissue to selective phosphodiesterase inhibitors.
2007
2007
Structure determination of new analogues of vardenafil and sildenafil in dietary supplements
New analogues of vardenafil and sildenafil illegally added to dietary supplements were detected by high-performance liquid… 
Review
2006
Review
2006
Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction.
Review
2005
Review
2005
Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.
Review
2005
Review
2005
Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors.
Review
2001
Review
2001
Oral drug therapy for erectile dysfunction.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)